WELCOME TO The Biotechnology REPORT
Biotech Experts Inc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
Q&#178; Solutions and IQVIA, Tasso | October 07, 2022
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
Developed in collaboration with Tasso Inc, a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-...
Samsung Biologics | July 21, 2021
Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Enlaza Therapeutics | December 19, 2022
Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...
MEDTECH, INDUSTRIAL IMPACT
Oxford Biomedica Solutions LLC | December 15, 2022
Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies. This places Oxford Biomedica Solutions ahead of the previously stated target of two new partners by the end of the calendar year.
Under these additional agreements, Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ gene therapy programs, which cover a...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE